Article
Multidisciplinary Sciences
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Summary: By sequencing circulating tumor DNA in patients from the FLAURA trial, this study identifies MET amplification and EGFR C797S mutation as the most frequent acquired resistance mechanisms to first-line osimertinib.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Liping Kang, Jianliang Mai, Weiting Liang, Qihua Zou, Caiwen Huang, Yongbin Lin, Ying Liang
Summary: This study retrospectively evaluated the efficacy and safety of afatinib as first-line treatment for EGFR-mutant NSCLC patients with brain metastases. The results showed that afatinib demonstrated encouraging efficacy on brain metastases, especially in patients with common EGFR mutations.
FRONTIERS IN ONCOLOGY
(2023)
Review
Medicine, General & Internal
Yimin Wang, Chuling Li, Zimu Wang, Zhaofeng Wang, Ranpu Wu, Ying Wu, Yong Song, Hongbing Liu
Summary: This systematic review evaluated the efficacy and safety of immunotherapy in early and late lung cancer, finding that immunotherapy has better efficacy in early lung cancer compared to advanced lung cancer, especially when combined with chemotherapy. In terms of safety, immunotherapy, either alone or in combination with other therapies, was found to be safer in early lung cancer than in advanced lung cancer.
Review
Oncology
Qianqian Sun, Weiqing Li, Taorui Liu, Huiqin Guo
Summary: This article presents a case of a middle-aged male patient with advanced-stage lung cancer, highlighting the importance of individualized chemotherapy combined with immunotherapy and surgery. The patient achieved complete response and prolonged survival time after a course of preoperative chemotherapy, surgery, and postoperative chemotherapy. The development of precise individualized chemotherapy plans based on comprehensive analysis of patient characteristics is a major direction for future lung cancer treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Tony S. Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Alka Chawla, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam Pluzanski, Kay Noonan, Yiyun Tang, Malaika Pastel, Keith D. Wilner, Yi-Long Wu
Summary: This study provides an updated analysis of overall survival in patients with advanced NSCLC and EGFR-activating mutations treated with dacomitinib versus gefitinib. The OS benefit from first-line treatment with dacomitinib was maintained after extended follow-up, indicating its efficacy in this patient population.
Article
Multidisciplinary Sciences
Joyce H. S. You, William C. S. Cho, Wai-Kit Ming, Yu-Chung Li, Chung-Kong Kwan, Kwok-Hung Au, Joseph Siu-Kie Au
Summary: The study compared EGFR mutation-guided target therapy with empirical chemotherapy for first-line treatment of advanced NSCLC in the public healthcare setting of Hong Kong. Results showed that EGFR mutation-guided erlotinib appears to be the cost-effective strategy from the perspective of Hong Kong public healthcare provider across a range of willingness-to-pay levels.
Article
Oncology
Lan-Lan Pang, Jia-Di Gan, Jia-Rong Tan, Yi-Hua Huang, Jun Liao, Wei-Ting Liang, Peng-Bo Deng, Wen-Feng Fang
Summary: This study revealed the differential benefits of afatinib in NSCLC patients with different mutation genotypes and identified potential resistance mechanisms in patients with EGFR G719X/L861Q/S768I for the first time. The findings have practical implications for guiding optimal treatment in clinical practice.
Article
Oncology
Christos Chouaid, Thomas Filleron, Didier Debieuvre, Maurice Perol, Nicolas Girard, Eric Dansin, Herve Lena, Radj Gervais, Sophie Cousin, Josiane Otto, Roland Schott, David Planchard, Anne Madroszyk, Coureche Kaderbhai, Pascale Dubray-Longeras, Sandrine Hiret, Eric Pichon, Christelle Clement-Duchene, Gaelle Chenuc, Gaetane Simon, Lise Bosquet, Xavier QUantin
Summary: Data on EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC) in Europe are limited. A large real-world cohort study assessed the characteristics and outcomes of non-squamous (nsq) NSCLC patients harboring EGFR exon 20 insertion mutations. The study found that EGFR exon 20 insertion mutations are rare (0.6%) and have a prognosis similar to wild-type EGFR but worse than common EGFR mutations, emphasizing the need for advancements in treatment for this rare population.
Article
Oncology
Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi-Hyun Kim, Sung Yong Lee, Cheol-Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon
Summary: Sequential treatment with afatinib and osimertinib showed better survival rates in NSCLC patients with EGFR mutations compared to treatment with afatinib followed by other chemotherapies.
Article
Oncology
Jia Li Low, Yiqing Huang, Kenneth Sooi, Yvonne Ang, Zhi Yao Chan, Katie Spencer, Anand Devaprasath Jeyasekharan, Raghav Sundar, Boon Cher Goh, Ross Soo, Wei Peng Yong
Summary: The study found that there was no significant difference in survival outcomes, toxicity, and costs between 100 mg and 200 mg doses of pembrolizumab in the treatment of advanced non-small cell lung cancer. The lower dose of 100 mg showed potential cost savings without compromising efficacy, suggesting the need for further investigation through a randomized trial.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Cell Biology
Kentaro Tanaka, Kenji Chamoto, Sho Saeki, Ryusuke Hatae, Yuki Ikematsu, Kazuko Sakai, Nobuhisa Ando, Kazuhiro Sonomura, Shinsuke Kojima, Masanori Taketsuna, Young Hak Kim, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Tomoko Hirano, Fumihiko Matsuda, Toyohiro Hirai, Kazuto Nishio, Takuro Sakagami, Masanori Fukushima, Yoichi Nakanishi, Tasuku Honjo, Isamu Okamoto
Summary: Researchers conducted a clinical trial of bezafibrate in combination with nivolumab for advanced non-small cell lung cancer patients. The combination therapy was well tolerated and showed potential in promoting T cell function and extending the duration of response. This T cell metabolism-targeting combination strategy may have implications for maintaining the antitumor activity of immune checkpoint inhibitors and requires further validation.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Nian N. N. Maarof, Emilia Abdulmalek, Sharida Fakurazi, Mohd Basyaruddin Abdul Rahman
Summary: This study presents the synthesis and characterization of carbonate apatite nanoparticles (nCA) as a drug delivery system for lung cancer treatment. The results show that nCA can effectively encapsulate the drug afatinib and exhibit slow and sustained drug release, suggesting its potential as a promising treatment for lung cancer.
Article
Multidisciplinary Sciences
Dongliang Bian, Liangdong Sun, Junjie Hu, Liang Duan, Haoran Xia, Xinsheng Zhu, Fenghuan Sun, Lele Zhang, Huansha Yu, Yicheng Xiong, Zhida Huang, Deping Zhao, Nan Song, Jie Yang, Xiao Bao, Wei Wu, Jie Huang, Wenxin He, Yuming Zhu, Gening Jiang, Peng Zhang
Summary: This study aimed to assess the feasibility of neoadjuvant Afatinib treatment for stage III NSCLC patients. The results showed that Afatinib improved the objective response rate (ORR) in NSCLC patients and caused dynamic changes in the tumor microenvironment.
NATURE COMMUNICATIONS
(2023)
Article
Multidisciplinary Sciences
Ming-Hung Chang, Kuo-Hwa Chiang, Jiunn-Min Shieh, Kuo-Chen Cheng, Chung-Han Ho
Summary: Miliary lung metastasis is not a dominant indicator for outcome evaluation in patients with non-small cell lung cancer harboring EGFR mutation under TKI prescription. Other strong prognostic indicators include performance status, liver metastasis, EGFR type, and generation of TKI.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Masaaki Okajima, Satoru Miura, Satoshi Watanabe, Hiroshi Tanaka, Kazuhiko Ito, Takashi Ishida, Masato Makino, Akira Iwashima, Naoya Matsumoto, Kazuhiro Sato, Kosuke Ichikawa, Tetsuya Abe, Hirohisa Yoshizawa, Toshiaki Kikuchi
Summary: This study aimed to evaluate the efficacy of multimodal prophylactic treatment for afatinib-induced toxicity. However, prophylactic loperamide administration was not effective in preventing severe or intolerable diarrhea. Adequate dose reduction may be a better approach to manage afatinib-induced diarrhea.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)